Products
Alethia is focusing on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition, three areas for which there are very few therapeutic options.
AB-25E9 – inhibition of bone degradation
- Alethia is developing a first-in-class bone antiresorptive for the treatment of bone loss in acute disorders such a hypercalcemia of malignancy, bone and cartilage loss in inflammatory disorders and severe osteoporosis. Read more about AB-25E9
AB-3A4 – invasive carcinomas
- Alethia is developing a therapeutic monoclonal antibody for the treatment of ovarian cancer and other invasive carcinomas such as triple-negative breast tumors and renal cancer. AB-3A4 is an IgG1 monoclonal antibody against KAAG-1, a cell-surface protein involved in tumor invasion. Read more about AB-3A4
AB-16B5 – inhibition of EMT
- Alethia is developing an inhibitor of EMT for the treatment of invasive carcinomas. AB-16B5 is a humanized IgG2 antibody against an EMT-inducing form of secreted clusterin (sCLU). AB-16B5 very efficiently blocks EMT and pre-clinical data indicate that animals xenografted with various carcinoma cells show an increase of response to standard of care chemotherapy as well as a reduction of invasion. Read more about AB-16B5
News
- May 29, 2013 Alethia Biotherapeutics Announce Entry into Licensing and Research Agreements for its Inhibitor of EMT with IBC Generium Alethia 130529 EN...
- May 16, 2013 Alethia Biotherapeutics Announces the Issuance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT Alethia 130516 EN...
- February 28, 2013 Alethia Biotherapeutics Announces Notice of Allowance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT Alethia 130228 EN...
Events
- June 14, 2013 Alethia Biotherapeutics is pleased to support its "Moon Walkers" team who is participating in this year's Canadian Cancer Society Relay For Life, an overnight non-competitive relay that celebrates cancer survivors and pays tribute to loved ones....
- May 31 - June 4, 2013 Alethia Biotherapeutics to be part of the ASCO 2013 Annual Meeting in Chicago, USA Mario Filion and Gilles Tremblay will be in attendance....
- April 22 - 25, 2013 Alethia Biotherapeutics to be part of the 2013 BIO International Convention in Chicago, USA. Yves Cornellier and Mario Filion will be in attendance....